| abstract |
A series of compounds represented by the structural formula and their pharmaceutically acceptable isomers, salts, solvates or polymorphs are disclosed. Also disclosed are pharmaceutical compositions containing the compounds and their use as thrombin receptor antagonists and as binding agents for cannabinoid receptors. The present invention relates to thrombin receptor antagonists in the treatment of thrombosis, atherosclerosis, restenosis, hypertension, angina, arrhythmia, heart failure, cerebral ischemia, stroke, neurodegenerative diseases, and cancer-related diseases. As a norsecohimbacine derivative. |